Group A Streptococcal vaccine candidate: Contribution of epitope to size, antigen presenting cell interaction and immunogenicity

Nanomedicine

Volumn 9, Issue 17, 2014, Pages 2613-2624

  Zaman, Mehfuz ^a,b   Chandrudu, Saranya ^a   Giddam, Ashwini K ^a   Reiman, Jennifer ^b   Skwarczynski, Mariusz ^a   Mcphun, Virginia ^b   Moyle, Peter M ^a   Batzloff, Michael R ^b   Good, Michael F ^b   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Group A Streptococcus; lipopeptide; peptide epitope; self adjuvanting vaccine; self assembled nanoparticles

Indexed keywords

EPITOPE; LIPOPEPTIDE; STREPTOCOCCUS VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PEPTIDE SYNTHESIS; STREPTOCOCCUS GROUP A; VACCINATION;

EID: 84919784550     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.190     Document Type: Article

References (45)

1. Ralph AP, Carapetis JR. Group A Streptococcal diseases and their global burden. Curr. Top. Microbiol. Immunol., 368, 1-27 (2012).
2. Henningham A, Gillen CM, Walker MJ. Group A Streptococcal vaccine candidates: Potential for the development of a human vaccine. Curr. Top. Microbiol. Immunol. 368, 207-2042 (2012).
3. Thomas CL, Lee SW. Knowing is half the battle: Targeting virulence factors of group A Streptococcus for vaccine and therapeutics. Curr. Drug Targets 13(3), 308-322 (2012).
4. Batzloff MR, Sriprakash KS, Good MF. Vaccine development for group A Streptococcus infections and associated disease. Curr. Drug Targets 5(1), 57-69 (2004).
5. Smith MT, Zurynski Y, Lester-Smith D, Elliott E, Carapetis J. Rheumatic fever-identification, management and secondary prevention. Aust. Fam. Physician 41(1-2), 31-35 (2012).
6. Parks T, Smeesters PR, Steer AC. Streptococcal skin infection and rheumatic heart disease. Curr. Opin. Infect. Dis. 25(2), 145-153 (2012).
7. Adderson EE, Shikhman AR, Ward KE, Cunningham MW. Molecular analysis of polyreactive monoclonal antibodies from rheumatic carditis: Human anti-N-Acetylglucosamine/ anti-myosin antibody V region genes. J. Immunol. 161(4), 2020-2031 (1998).
8. Dale JB, Beachey EH. Sequence of myosin-crossreactive epitopes of streptococcal M protein. J. Exp. Med. 164(5), 1785-1790 (1986).
9. Eriksson BK, Villasenor-Sierra A, Norgren M, Stevens DL. Opsonization of T1M1 group A Streptococcus: Dynamics of antibody production and strain specificity. Clin. Infect. Dis. 32(2), E24-E30 (2001).
10. Brandt ER, Hayman WA, Currie B et al. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology 89(3), 331-337 (1996).
11. Dale JB, Penfound TA, Chiang EY, Walton WJ. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 29(46), 8175-8178 (2011).
12. Zaman M, Abdel-Aal AB, Fujita Y et al. Structure-Activity relationship for the development of a self-Adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes. J. Med. Chem. 55(19), 8515-8523 (2012).
13. Pandey M, Batzloff MR, Good MF. Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: Contribution of B and T-cells towards protection. PLoS ONE 4(4), e5147 (2009).
14. Smeesters PR, McMillan DJ, Sriprakash KS, Georgousakis MM. Differences among group A Streptococcus epidemiological landscapes: Consequences for M protein-based vaccines? Expert Rev. Vaccines 8(12), 1705-1720 (2009).
15. Pandey M, Batzloff MR, Good MF. Vaccination against rheumatic heart disease: A review of current research strategies and challenges. Curr. Infect. Dis. Rep. 14(4), 381-390 (2012).
16. Penfound TA, Chiang EY, Ahmed EA, Dale JB. Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes. Vaccine 28(31), 5017-5022 (2010).
17. Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A Streptococcus. Int. Immunol. 9(11), 1723-1733 (1997).
18. Zeng W, Azzopardi K, Hocking D et al. A totally synthetic lipopeptide-based self-Adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli. Vaccine 30(32), 4800-4806 (2012).
19. Amiset L, Fend L, Gatard-Scheikl T et al. TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy. Oncoimmunology 1(8), 1271-1280 (2012).
20. Renaudet O, Dasgupta G, Bettahi I et al. Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity. PLoS ONE 5(6), e11216 (2010).
21. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11(4 Suppl.), S63-S68 (2005).
22. Van Bergenhenegouwen J, Plantinga TS, Joosten LA et al. TLR2 & Co: A critical analysis of the complex interactions between TLR2 and coreceptors. J. Leukoc. Biol. 94(5), 885-902 (2013).
23. Tsunoda I, Sette A, Fujinami RS et al. Lipopeptide particles as the immunologically active component of CTL inducing vaccines. Vaccine 17(7-8), 675-685 (1999).
24. Abdel-Aal AB, Al-Isae K, Zaman M, Toth I. Simple synthetic Toll-like receptor 2 ligands. Bioorg. Med. Chem. Lett. 21(19), 5863-5865 (2011).
25. Benmohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect. Dis. 2(7), 425-431 (2002).
26. Batzloff MR, Hartas J, Zeng W, Jackson DC, Good MF. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-Adjuvanting lipid protects mice from group A Streptococcus challenge and reduces throat colonization. J. Infect. Dis. 194(3), 325-330 (2006).
27. Zaman M, Abdel-Aal AB, Fujita Y et al. Immunological evaluation of lipopeptide group A Streptococcus (GAS) vaccine: Structure-Activity relationship. PLoS ONE 7(1), e30146 (2012).
28. Skwarczynski M, Dougall AM, Khoshnejad M et al. Peptide-based subunit vaccine against hookworm infection. PLoS ONE 7(10), e46870 (2012).
29. Nicolaou A, Kokotos G, Constantinou-Kokotou V et al. Synthesis and properties of novel lipopeptides and lipid mimetics. J. Pept. Sci. 3(4), 291-298 (1997).
30. Zaman M, Abdel-Aal AB, Phillipps KS, Fujita Y, Good MF, Toth I. Structure-Activity relationship of lipopeptide Group A Streptococcus (GAS) vaccine candidates on Toll-like receptor 2. Vaccine 28(10), 2243-2248 (2010).
31. Cemazar M, Craik DJ. Microwave-Assisted Boc-solid phase peptide synthesis of cyclic cysteine-rich peptides. J. Pept. Sci. 14(6), 683-689 (2008).
32. Abdel-Aal AB, Batzloff MR, Fujita Y et al. Structure-Activity relationship of a series of synthetic lipopeptide self-Adjuvanting group a streptococcal vaccine candidates. J. Med. Chem. 51(1), 167-172 (2008).
33. Bauer MJ, Georgousakis MM, Vu T et al. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein. Vaccine 30(12), 2197-2205 (2012).
34. Moyle PM, Olive C, Ho MF, Good MF, Toth I. Synthesis of a highly pure lipid core peptide based self-Adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation. J. Med. Chem. 49(21), 6364-6370 (2006).
35. Claassen IJ, Osterhaus AD, Poelen M, Van Rooijen N, Claassen E. Antigen detection in vivo after immunization with different presentation forms of rabies virus antigen, II. Cellular, but not humoral, systemic immune responses against rabies virus immune-stimulating complexes are macrophage dependent. Immunology 94(4), 455-460 (1998).
36. Tabas I, Lim S, Xu XX, Maxfield FR. Endocytosed beta-VLDL and LDL are delivered to different intracellular vesicles in mouse peritoneal macrophages. J. Cell Biol. 111(3), 929-940 (1990).
37. Packard RR, Maganto-Garcia E, Gotsman I, Tabas I, Libby P, Lichtman AH. CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ. Res. 103(9), 965-973 (2008).
38. Lin HH, Faunce DE, Stacey M et al. The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance. J. Exp. Med. 201(10), 1615-1625 (2005).
39. Drenou B, Amiot L, Setterblad N et al. MHC class II signaling function is regulated during maturation of plasmacytoid dendritic cells. J. Leukoc. Biol. 77(4), 560-567 (2005).
40. Steer AC, Dale JB, Carapetis JR. Progress toward a global group a streptococcal vaccine. Pediatr. Infect. Dis. J. 32(2), 180-182 (2013).
41. Skwarczynski M, Parhiz BH, Soltani F et al. Lipid peptide core nanoparticles as multivalent vaccine candidates against Streptococcus pyogenes. Aust. J. Chem. 65(1), 35-39 (2012).
42. Skwarczynski M, Toth I. Peptide-based subunit nanovaccines. Curr. Drug Deliv. 8(3), 282-289 (2011).
43. Zaman M, Good MF, Toth I. Nanovaccines and their mode of action, Methods 60, 226-231 (2013).
44. Giddam AK, Zaman M, Skwarczynski M, Toth I. Liposome-based delivery system for vaccine candidates: Constructing an effective formulation, Nanomedicine (London) 7, 1877-1893 (2012).
45. Brandt ER, Sriprakash KS, Hobb RI et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat. Med. 6(4), 455-459 (2000).